US HB7474 | 2021-2022 | 117th Congress
Status
Spectrum: Partisan Bill (Democrat 16-0)
Status: Introduced on April 7 2022 - 25% progression, died in committee
Action: 2022-04-08 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on April 7 2022 - 25% progression, died in committee
Action: 2022-04-08 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To amend the Public Health Service Act to increase the transparency of pharmaceutical research costs, and for other purposes.
Title
Pharmaceutical Research Transparency Act of 2022
Sponsors
| Rep. Carolyn Maloney [D-NY] | Rep. Janice Schakowsky [D-IL] | Sen. Peter Welch [D-VT] | Rep. Katie Porter [D-CA] |
| Rep. Mark DeSaulnier [D-CA] | Rep. Jamie Raskin [D-MD] | Rep. Ann Kuster [D-NH] | Rep. Eleanor Norton [D-DC] |
| Rep. Raul Grijalva [D-AZ] | Rep. Mary Gay Scanlon [D-PA] | Rep. Mark Takano [D-CA] | Rep. Peter DeFazio [D-OR] |
| Rep. Judy Chu [D-CA] | Rep. Nanette Barragan [D-CA] | Rep. Mark Pocan [D-WI] | Rep. Pramila Jayapal [D-WA] |
History
| Date | Chamber | Action |
|---|---|---|
| 2022-04-08 | House | Referred to the Subcommittee on Health. |
| 2022-04-07 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2022-04-07 | House | Introduced in House |
Same As/Similar To
SB4037 (Same As) 2022-04-07 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/117th-congress/house-bill/7474/all-info |
| Text | https://www.congress.gov/117/bills/hr7474/BILLS-117hr7474ih.pdf |
